Loading..

United Therapeutics Corporation (UTHR) Report Analysis

Corporate Events

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) ...

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Defensive Index

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) ...

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

Neutral

United Therapeutics Corporation Presents at Rea...

2022-06-13 18:52:00

United Therapeutics Corporation Presents at Realcomm Conference 2022, Jun-15-2022 01:30 PM. Venue: Orlando, Florida, United States. Speakers: ...

Neutral

United Therapeutics Corporation Presents at 202...

2022-06-03 20:30:00

United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:00 AM. Venue: Marriott Marquis, New Yo...

Positive

United Therapeutics Corporation Announces FDA A...

2022-05-24 10:00:00

United Therapeutics Corporation announced that the U.S. Food and Drug Administration has approved Tyvaso DPI™ (treprostinil) inhalation powder...

Neutral

Realcomm Conference Group, LLC, Realcomm Confer...

2022-05-02 11:21:00

Realcomm Conference Group, LLC, Realcomm Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Orlando, Florida, United States.

Neutral

United Therapeutics Corporation - Shareholder/A...

2022-04-29 10:01:00

AGM

Neutral

United Therapeutics Corporation, Annual General...

2022-04-29 10:01:00

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022, at 10:30 US Eastern Standard Time. Agenda: To consider election of the ...

Neutral

United Therapeutics Corporation Presents at Ame...

2022-04-29 10:00:00

United Therapeutics Corporation Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022. Venue: S...

Neutral

United Therapeutics Corporation, Q1 2022 Earnin...

2022-04-27 13:18:00

United Therapeutics Corporation, Q1 2022 Earnings Call, May 04, 2022

Neutral

United Therapeutics Corporation to Report Q1, 2...

2022-04-27 10:00:00

United Therapeutics Corporation announced that they will report Q1, 2022 results Pre-Market on May 04, 2022

Positive

United Therapeutics Corporation Enters into Cre...

2022-04-01 10:14:00

On March 31, 2022, United Therapeutics Corporation entered into a Credit Agreement with certain of its subsidiaries party thereto, as guaranto...

Neutral

HMG Strategy, LLC, 2022 New York CIO Summit of ...

2022-03-03 20:59:00

HMG Strategy, LLC, 2022 New York CIO Summit of America, Apr 05, 2022. Venue: Pier 59, Chelsea Piers, Manhattan, New York, United States.

Neutral

United Therapeutics Corporation Presents at 202...

2022-03-03 20:59:00

United Therapeutics Corporation Presents at 2022 New York CIO Summit of America, Apr-05-2022 10:55 AM. Venue: Pier 59, Chelsea Piers, Manhatta...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Positive

United Therapeutics Corporation Receives Comple...

2021-12-27 11:31:00

United Therapeutics Corporation (“UT”) announced that it had received a Complete Response from the U.S. Food and Drug Administration (the “FDA...

Neutral

American Thoracic Society, Inc, American Thorac...

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francic...

Positive

3D Systems and United Therapeutics Corporation ...

2021-10-27 20:25:00

3D Systems announced an expansion of its joint development program with United Therapeutics Corporation. The development and license agreement...

Neutral

United Therapeutics Corporation, Q3 2021 Earnin...

2021-10-27 10:00:00

United Therapeutics Corporation, Q3 2021 Earnings Call, Nov 03, 2021

Neutral

United Therapeutics Corporation to Report Q3, 2...

2021-10-27 10:00:00

United Therapeutics Corporation announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Positive

United Therapeutics Corporation Details New Dat...

2021-10-21 10:00:00

United Therapeutics Corporation detailed the new clinical and real-world evidence on pulmonary arterial hypertension (PAH) and pulmonary hyper...

Neutral

MannKind Corporation and United Therapeutics Co...

2021-10-18 20:02:00

On October 16, 2021, MannKind Corporation (“MannKind”) and United Therapeutics Corporation (“United Therapeutics”) entered into an amendment (...

Positive

United Therapeutics Corporation Provides an Upd...

2021-10-18 10:00:00

United Therapeutics Corporation announced an update on the U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) fo...

Positive

United Therapeutics to Present New Data At Ches...

2021-10-11 10:00:00

United Therapeutics Corporation announced new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interst...

Neutral

United Therapeutics Corporation Presents at 30t...

2021-10-01 10:34:00

United Therapeutics Corporation Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM. Venue: Rancho Palos Verdes,...

Neutral

United Therapeutics Corporation Approves Amendm...

2021-10-01 10:01:00

United Therapeutics Corporation, at the Special Meeting of Shareholders held on September 30, 2021 the Company’s shareholders approved an amen...

Positive

United Therapeutics Corporation to Present Tyva...

2021-08-24 10:00:00

United Therapeutics Corporation announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulm...

Neutral

United Therapeutics Corporation Proposes Amendm...

2021-08-19 10:02:00

United Therapeutics Corporation at its special meeting for shareholders to be held on September 30, 2021, proposed an amendment to Restated Ce...

Neutral

United Therapeutics Corporation - Shareholder/A...

2021-08-19 10:01:00

Special meeting of shareholders

Neutral

United Therapeutics Corporation, Special/Extrao...

2021-08-19 10:01:00

United Therapeutics Corporation, Special/Extraordinary Shareholders Meeting, Sep 30, 2021, at 10:30 US Eastern Standard Time. Agenda: To consi...

Neutral

United Therapeutics Corporation has filed a She...

2021-08-04 00:00:00

United Therapeutics Corporation has filed a Shelf Registration in the amount of $180.66 million. Security Name: Common Stock Securities Of...

Neutral

United Therapeutics Corporation Presents at 12t...

2021-08-03 10:00:00

United Therapeutics Corporation Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 08:35 AM.

Neutral

United Therapeutics Corporation to Report Q2, 2...

2021-07-28 10:00:00

United Therapeutics Corporation announced that they will report Q2, 2021 results Pre-Market on Aug 04, 2021

Neutral

United Therapeutics Corporation, Q2 2021 Earnin...

2021-07-28 10:00:00

United Therapeutics Corporation, Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Defensive Index

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Defensive Index

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

Neutral

United Therapeutics Corporation Presents at Realcomm Conference 2022, Jun-15-2022 01:30 PM

2022-06-13 18:52:00

United Therapeutics Corporation Presents at Realcomm Conference 2022, Jun-15-2022 01:30 PM. Venue: Orlando, Florida, United States. Speakers: Thomas Kaufman.

Neutral

United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:00 AM

2022-06-03 20:30:00

United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: James C. Edgemond, CFO & Treasurer.

Positive

United Therapeutics Corporation Announces FDA Approval of Tyvaso DPI

2022-05-24 10:00:00

United Therapeutics Corporation announced that the U.S. Food and Drug Administration has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD. PAH is life-threatening high blood pressure in the arteries of the lungs, affecting the ability of the heart and lungs to work properly. PAH affects an estimated 45,000 patients in the United States. Interstitial lung disease (ILD) is a group of conditions in which marked scarring occurs within the lungs. It is often complicated by pulmonary hypertension (PH; high blood pressure in the lungs), which furthers symptoms and decreases survival. PH is estimated to affect at least 15% of patients with early-stage ILD (approximately 30,000 PH-ILD patients in the United States) and may affect up to 86% of patients with more severe ILD. Tyvaso® (treprostinil) Inhalation Solution and Tyvaso DPI are the only therapies approved by the FDA to treat PH-ILD. FDA approval of the new drug application for Tyvaso DPI is supported by data from BREEZE, an open label study of 51 PAH patients on a stable regimen of Tyvaso Inhalation Solution who were transitioned to Tyvaso DPI. In subjects with PAH, transition from Tyvaso Inhalation Solution to Tyvaso DPI demonstrated safety and tolerance during the three-week treatment phase with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes. Top line data from BREEZE were issued in January 2021, efficacy data were presented in September 2021, long-term open-label safety data were published in April 2022, and additional long-term safety and efficacy data were presented in May 2022.

Neutral

Realcomm Conference Group, LLC, Realcomm Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-05-02 11:21:00

Realcomm Conference Group, LLC, Realcomm Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Orlando, Florida, United States.

Neutral

United Therapeutics Corporation - Shareholder/Analyst Call

2022-04-29 10:01:00

AGM

Neutral

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022

2022-04-29 10:01:00

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022, at 10:30 US Eastern Standard Time. Agenda: To consider election of the nine directors named in this Proxy Statement; to consider Advisory resolution to approve executive compensation; to consider approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan; to consider ratification of the appointment of Ernst & Young LLP as company independent registered public accounting firm for 2022.

Neutral

United Therapeutics Corporation Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022

2022-04-29 10:00:00

United Therapeutics Corporation Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022. Venue: San Francicso, California, United States. Presentation Date & Speakers: May-15-2022, Elizabeth S. Klings, M.D., Boston University School of Medicine, R James White, Ph.D., University of Rochester. May-16-2022, Aaron B Waxman, Brigham and Women’s Hospital, Boston.

Neutral

United Therapeutics Corporation, Q1 2022 Earnings Call, May 04, 2022

2022-04-27 13:18:00

United Therapeutics Corporation, Q1 2022 Earnings Call, May 04, 2022

Neutral

United Therapeutics Corporation to Report Q1, 2022 Results on May 04, 2022

2022-04-27 10:00:00

United Therapeutics Corporation announced that they will report Q1, 2022 results Pre-Market on May 04, 2022

Positive

United Therapeutics Corporation Enters into Credit Agreement

2022-04-01 10:14:00

On March 31, 2022, United Therapeutics Corporation entered into a Credit Agreement with certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association, as administrative agent and as a swingline lender. The Credit Agreement provides for (i) an unsecured, revolving credit facility of up to $1.2 billion; and (ii) a second unsecured, revolving credit facility of up to $800 million. The facilities mature five years after the closing date of the Credit Agreement, subject to an ability of the lenders thereunder, or certain of the lenders thereunder, to elect to extend the maturity date of their commitments by one year following a request for such extension by the Company in accordance with the terms of the Credit Agreement, up to a maximum of two such extensions. As of March 31, 2022, Lung Biotechnology PBC is the only subsidiary of the Company required to be a Guarantor and guarantee the Company’s obligations under the Credit Agreement. From time to time, one or more additional subsidiaries of the Company may be required to guarantee the Company’s obligations under the Credit Agreement. At the Company’s option, the loan will bear interest at either an adjusted Term SOFR rate or a fluctuating base rate, in each case, plus an applicable margin that is determined on a quarterly basis based on the Company’s consolidated total leverage ratio (as calculated in accordance with the Credit Agreement). The proceeds of borrowings under the Credit Agreement are available to refinance certain existing indebtedness of the Company and its subsidiaries and/or for working capital and other general corporate purposes. Upon closing of the Credit Agreement on March 31, 2022, the Company borrowed $800.0 million under the Credit Agreement, and used the funds to repay outstanding indebtedness under the 2018 Credit Agreement discussed under Item 1.02 below. The Credit Agreement also contains customary affirmative and negative covenants that, among other things, limit the ability of the Company and its subsidiaries to: (a) incur indebtedness; (b) grant liens; (c) enter into a merger, consolidation, or amalgamation; (d) liquidate, wind up, or dissolve; or (e) sell all or substantially all of the property, business, or assets of the Company and its subsidiaries taken as a whole. In addition, as of the last day of each fiscal quarter, the Company must not permit (i) a consolidated ratio of total indebtedness to EBITDA to be greater than 3.00 to 1.00 (which ratio may, upon consummation of certain qualifying acquisitions, be increased to 3.50 to 1.00 for four fiscal quarters following such acquisition); and (ii) its consolidated interest coverage ratio to be less than 3.00 to 1.00, in each case calculated in accordance with the Credit Agreement. The Credit Agreement contains customary events of default, including a change of control. Upon the occurrence and continuation of an event of default, all amounts due under the Credit Agreement and the other loan documents become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of the lenders), immediately due and payable.

Neutral

HMG Strategy, LLC, 2022 New York CIO Summit of America, Apr 05, 2022

2022-03-03 20:59:00

HMG Strategy, LLC, 2022 New York CIO Summit of America, Apr 05, 2022. Venue: Pier 59, Chelsea Piers, Manhattan, New York, United States.

Neutral

United Therapeutics Corporation Presents at 2022 New York CIO Summit of America, Apr-05-2022 10:55 AM

2022-03-03 20:59:00

United Therapeutics Corporation Presents at 2022 New York CIO Summit of America, Apr-05-2022 10:55 AM. Venue: Pier 59, Chelsea Piers, Manhattan, New York, United States. Speakers: Shola Oyewole, Vice President of Digital Innovation.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Positive

United Therapeutics Corporation Receives Complete Response from the U.S. Food and Drug Administration

2021-12-27 11:31:00

United Therapeutics Corporation (“UT”) announced that it had received a Complete Response from the U.S. Food and Drug Administration (the “FDA”) concerning UT’s new drug application (“NDA”) for Tyvaso DPI™. On December 27, 2021, UT disclosed that it had resubmitted the NDA to the FDA.

Neutral

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francicso, California, United States.

Positive

3D Systems and United Therapeutics Corporation Announce Expansion of Bioprinting Program

2021-10-27 20:25:00

3D Systems announced an expansion of its joint development program with United Therapeutics Corporation. The development and license agreement, first established in 2017, combines the 3D printing expertise of 3D Systems, with the regenerative medicine and organ manufacturing expertise of United Therapeutics (UT). To date, the program has had a strong, singular focus on developing the capability to print scaffolds for human lungs using a process call Print to Perfusion™. This 3D printed scaffold would then be cellularized using cells derived from the recipient patient’s own body, to create personalized human lungs. 3D Systems has focused primarily on establishing the printing technology to produce scaffolds meeting the extreme precision and resolution requirements for a functional human lung and to do so in a manner that yields the physical, mechanical, and biocompatibility performance to influence cell behavior and reproduction required for extended use in the human body. The goal of the program is to establish an unlimited supply of human lungs, requiring no immunosuppression, allowing all patients with end-stage lung disease to receive transplants which will enable them to enjoy long and active lives. Based upon the progress made toward this goal, the program is now being expanded to include two additional human organs, with support now designated through 2025.

Neutral

United Therapeutics Corporation, Q3 2021 Earnings Call, Nov 03, 2021

2021-10-27 10:00:00

United Therapeutics Corporation, Q3 2021 Earnings Call, Nov 03, 2021

Neutral

United Therapeutics Corporation to Report Q3, 2021 Results on Nov 03, 2021

2021-10-27 10:00:00

United Therapeutics Corporation announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Positive

United Therapeutics Corporation Details New Data Presented at Chest Annual Meeting 2021

2021-10-21 10:00:00

United Therapeutics Corporation detailed the new clinical and real-world evidence on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) presented at CHEST 2021, the annual meeting of the American College of Chest Physicians. United Therapeutics and its collaborators presented 10 abstracts across a broad range of studies in PAH and PH-ILD, including pharmacokinetic (PK) data from the BREEZE study of Tyvaso DPI.  Tyvaso DPI BREEZE pharmacokinetic data demonstrate similar exposure as Tyvaso: The CHEST meeting featured a poster detailing data from the BREEZE study of Tyvaso DPI in patients with PAH. New PK data presented at CHEST 2021 demonstrated that systemic exposure between Tyvaso DPI and Tyvaso was similar; in addition, lower variability in PK parameters were observed in Tyvaso DPI when compared with Tyvaso. PK data from a separate healthy volunteer study of Tyvaso DPI will be presented at a future scientific forum. The BREEZE study enrolled 51 subjects on a stable regimen of Tyvaso who were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution. Secondary objectives of the study included changes in six-minute walk distance (6WMD), device preference and satisfaction as evaluated through the Preference Questionnaire for Inhaled Treprostinil Devices, and patient-reported PAH symptoms and impact. Top line data showing the BREEZE study met its primary objective were released in January 2021, and detailed data on the primary and secondary objectives were presented in September 2021. United Therapeutics abstracts presented at CHEST 2021 included: Tyvaso abstracts: BREEZE: Clinical Outcomes and Pharmacokinetics (PK) of Treprostinil Inhalation Powder (Tyvaso DPI) Shelley Shapiro, MD; Leslie Spikes, MD; Ricardo Restrepo, MD; Joanna Joly, MD; Trushil Shah, MD; Jason Scoggin; Lisa Edwards, PhD; Peter Smith, PharmD; Melissa Miceli, PharmD. Inhaled treprostinil is currently delivered via a handheld ultrasonic nebulizer (Tyvaso Inhalation System). A dry powder formulation of treprostinil and a small, portable, inhaler (Tyvaso DPI) is in development for PAH. In patients with PAH, transition from Tyvaso to Tyvaso DPI was well-tolerated with significant improvements in 6MWD, device preference and satisfaction, and patient reported outcomes. Despite a 33% higher peak serum concentration (Cmax) observed for Tyvaso DPI vs. Tyvaso, the adverse event profiles were similar. Between-subject variability for area under the curve (AUC) and Cmax parameters was similar within treatment.  Dose-Response Analysis of Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Worsening. Victor Tapson, MD; Steven Nathan, MD, PhD; Micah Fisher, MD; H. James Ford, MD; James Gagermeier, MD; Joseph Parambil, MD; Amresh Raina, MD; Dianne Zwicke, MD; Alicia Gerke, MD; Eric Shen, PharmD; Dasum Lee, MS; Youlan Rao, PhD; Aaron Waxman, MD. In a post-hoc analysis of patients with PH-ILD in the INCREASE trial, patients were divided into two dose groups, less than nine breaths per session and nine breaths per session and above. The higher doses of inhaled treprostinil were associated with a lower risk of clinical worsening. These results underscore the importance of inhaled treprostinil dose titration in the context of adverse event management for patients with PH-ILD. The Impact of Hemodynamic Parameters on Inhaled Treprostinil Treatment Response – A Subgroup Analysis from the INCREASE Trial. Aaron Waxman, MD, PhD; Victor Tapson, MD; Reda Girgis, MD; James Runo, MD; Remzi Bag, MD; Arunabh Talwar, MD; Peter Smith, PharmD; Dana Johnson, PhD; Christine Park, PharmD; Steven Nathan, MD. This INCREASE post-hoc analysis evaluated the treatment effect of inhaled treprostinil on 6MWD and forced vital capacity (FVC) as a function of baseline hemodynamics in participants with PH-ILD. PH-ILD patients with higher pulmonary vascular resistance (PVR) and/or mean pulmonary artery pressure (mPAP) had a greater response to treatment. This analysis suggests higher PVR and mPAP reflect progressive pulmonary vascular remodeling and demonstrates the importance of considering pulmonary hemodynamics when treating patients with PH-ILD. Healthcare Resource Utilization and Treatment Patterns Before and After Initiation of Inhaled Treprostinil. Charles Burger, MD, FCCP; Christine Park, PharmD; Peter Classi, MSc, MBA; Andrew Nelsen, PharmD; Benjamin Wu, PharmD. In this retrospective analysis of real-world data, inhaled treprostinil was effective in reducing hospitalization, a known risk factor for poor outcomes. The benefit remained substantial even in patients on prior dual background therapy with an endothelin receptor antagonist and phosphodiesterase-5 inhibitor or soluble guanylate cyclase stimulator. Burden of Illness in Patients with Pulmonary Hypertension due to Interstitial Lung Disease: A Real-World Analysis Using US Claims Data. Gustavo Heresi, MD; Howard Castillo, NP-C; Henry Lee, PharmD; Peter Classi, MSc, MBA; Dana Stafkey-Mailey, PharmD, PhD; Kellie D. Morland, PharmD; Margaret Sketch, MPH, PharmD; Alexander Kantorovich, PharmD; Benjamin Wu, PharmD; Bonnie Dean, PhD. A retrospective cohort study of patients with PH-ILD was conducted using research databases to characterize healthcare resource utilization and costs associated with PH-ILD. Patients with PH-ILD have significantly increased utilization of healthcare resources, including inpatient admissions, and costs, following an initial diagnosis of pulmonary hypertension.

Neutral

MannKind Corporation and United Therapeutics Corporation Enter into an Amendment to the Commercial Supply Agreement

2021-10-18 20:02:00

On October 16, 2021, MannKind Corporation (“MannKind”) and United Therapeutics Corporation (“United Therapeutics”) entered into an amendment (the “Amendment”) to the commercial supply agreement, dated August 12, 2021, by and between MannKind and United Therapeutics (the “Supply Agreement”) to, among other things, extend the term of the Supply Agreement and amend the non-renewal notification periods. Under the amended Supply Agreement, unless earlier terminated, the term of the Supply Agreement continues until December 31, 2031 and is thereafter renewed automatically for additional, successive two-year terms unless (i) United Therapeutics provides notice to MannKind at least 24 months in advance of such renewal that United Therapeutics does not wish to renew the Supply Agreement or (ii) MannKind provides notice to United Therapeutics at least 48 months in advance of such renewal that MannKind does not wish to renew the Supply Agreement.

Positive

United Therapeutics Corporation Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application

2021-10-18 10:00:00

United Therapeutics Corporation announced an update on the U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Tyvaso DPI™, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), to improve exercise capacity. On October 15, 2021, the FDA issued a complete response declining to approve the NDA at this time. The FDA's letter noted only a single deficiency preventing approval of Tyvaso DPI, related to an open inspection issue at a third-party facility that performs analytical testing of treprostinil drug substance. In addition, the FDA did not cite any deficiencies or issues related to operations performed at the MannKind Corporation facility for manufacture, testing, and packaging of finished Tyvaso DPI, including its associated device. All other requests from the agency have been addressed. The draft labeling for Tyvaso DPI, as revised by FDA, includes the same indications as Tyvaso® (treprostinil) Inhalation Solution for PAH and PH-ILD, to improve exercise ability, and does not contain any contraindications or a boxed warning. The complete response also notes, but does not cite as a deficiency, that the FDA has not yet completed its review of a Citizen's Petition submitted to FDA in July 2021 concerning the safety of an excipient in Tyvaso DPI. TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration. Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).

Positive

United Therapeutics to Present New Data At Chest Annual Meeting 2021

2021-10-11 10:00:00

United Therapeutics Corporation announced new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented as posters at CHEST 2021.United Therapeutics and its collaborators are presenting a total of 10 abstracts across a broad range of studies in PAH and PH-ILD, including pharmacokinetic (PK) data from the BREEZE study of Tyvaso DPI™. The CHEST meeting will feature a poster detailing PK data from the BREEZE study of Tyvaso DPI in patients with PAH. The BREEZE study enrolled 51 subjects on a stable regimen of Tyvaso who were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution. Secondary objectives of the study included changes in six-minute walk distance, device preference and satisfaction as evaluated through the Preference Questionnaire for Inhaled Treprostinil Devices, and patient-reported PAH symptoms and impact. Top line data showing the BREEZE study met its primary objective were released in January 2021, and detailed data on the primary and secondary objectives were presented in September 2021. PK data from a healthy volunteer study of Tyvaso DPI will be presented at a future scientific forum. Other Tyvaso posters will detail subgroup data on dose response and hemodynamics collected during the INCREASE study of Tyvaso Inhalation Solution in patients with PH-ILD. Top line results from the INCREASE study were issued in February 2020 and additional data were issued in June 2020 and January 2021. Key Orenitram® posters include real world interim data from the ADAPT registry of Orenitram patients and an analysis of U.S. medical claims for Orenitram and selexipag patients one year into treatment. BREEZE: Clinical Outcomes and Pharmacokinetics (PK) of Treprostinil Inhalation Powder (Tyvaso DPI). Dose-response Analysis of Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Worsening. The Impact of Hemodynamic Parameters on Inhaled Treprostinil Treatment Response – A Subgroup Analysis from the INCREASE Trial. Healthcare Resource Utilization and Treatment Patterns Before and After Initiation of Inhaled Treprostinil. Burden of Illness in Patients with Pulmonary Hypertension due to Interstitial Lung Disease: A Real-World Analysis Using US Claims Data. Comparison of Effects of Inhaled Treprostinil on Lung Function in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease and Pulmonary Arterial Hypertension. Screening for Pulmonary Hypertension in Patients with Interstitial Lung Disease: Recommendations from a Delphi Consensus Panel. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

Neutral

United Therapeutics Corporation Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM

2021-10-01 10:34:00

United Therapeutics Corporation Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: Michael I. Benkowitz, President & COO.

Neutral

United Therapeutics Corporation Approves Amendment to Company’s Restated Certificate of Incorporation

2021-10-01 10:01:00

United Therapeutics Corporation, at the Special Meeting of Shareholders held on September 30, 2021 the Company’s shareholders approved an amendment to the Company’s Restated Certificate of Incorporation. The changes to the Certificate of Incorporation consist of the following: Adding language stating that the Company is a public benefit corporation; and Adding language to the Company’s statement of business purpose identifying the specific public benefits to be promoted by the Company.

Positive

United Therapeutics Corporation to Present Tyvaso Dpi™ Breeze Clinical Data At the European Respiratory Society International Congress 2021

2021-08-24 10:00:00

United Therapeutics Corporation announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2021, which will be held virtually from September 5-8, 2021. Data from the BREEZE study of Tyvaso DPI, a dry powder inhaled formulation of treprostinil, will be presented in a poster session on September 6, 2021. The BREEZE study enrolled 51 subjects on a stable regimen of Tyvaso® Inhalation Solution who were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution. Top line data showing the BREEZE study met its primary objective were released in January 2021.

Neutral

United Therapeutics Corporation Proposes Amendment to its Restated Certificate of Incorporation

2021-08-19 10:02:00

United Therapeutics Corporation at its special meeting for shareholders to be held on September 30, 2021, proposed an amendment to Restated Certificate of Incorporation to become a public benefit corporation.

Neutral

United Therapeutics Corporation - Shareholder/Analyst Call

2021-08-19 10:01:00

Special meeting of shareholders

Neutral

United Therapeutics Corporation, Special/Extraordinary Shareholders Meeting, Sep 30, 2021

2021-08-19 10:01:00

United Therapeutics Corporation, Special/Extraordinary Shareholders Meeting, Sep 30, 2021, at 10:30 US Eastern Standard Time. Agenda: To consider approval of an amendment to restated certificate of incorporation to become a public benefit corporation.

Neutral

United Therapeutics Corporation has filed a Shelf Registration in the amount of $180.66 million.

2021-08-04 00:00:00

United Therapeutics Corporation has filed a Shelf Registration in the amount of $180.66 million. Security Name: Common Stock Securities Offered: 1,000,000 Transaction Features: ESOP Related Offering

Neutral

United Therapeutics Corporation Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 08:35 AM

2021-08-03 10:00:00

United Therapeutics Corporation Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 08:35 AM.

Neutral

United Therapeutics Corporation to Report Q2, 2021 Results on Aug 04, 2021

2021-07-28 10:00:00

United Therapeutics Corporation announced that they will report Q2, 2021 results Pre-Market on Aug 04, 2021

Neutral

United Therapeutics Corporation, Q2 2021 Earnings Call, Aug 04, 2021

2021-07-28 10:00:00

United Therapeutics Corporation, Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Fundamental Summary

At a high level, the metrics from United Therapeutics's Q1 financial report release were demonstrably positive. Their positive income, growth, and value factors indicate that it is likely to continue to produce impressive results for the foreseeable future, as well. We expect that this positive performance will continue in the coming months, and anticipate that United Therapeutics will maintain good momentum even in a challenging environment. Therefore, they earned a total score of 88 out of 100 and a STRONG BUY recommendation.

United Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 461.9 million compared to USD 379.1 million a year ago. Net income was USD 239.9 million compared to USD 28.3 million a year ago. Basic earnings per share from continuing operations was USD 5.31 compared to USD 0.63 a year ago. Diluted earnings per share from continuing operations was USD 5.03 compared to USD 0.61 a year ago.

Business Description

United Therapeutics, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Sector Overview

United Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. United Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 5,359.8 3.7% 74
Liabilities 1,183.5 -2.2% 61
Price to Book 2.6 5.2% 88
Cash & Equivalents 813.3 -9.1% 60
Equity 4,176.3 5.5% 58
EBITDA 962.8 30.0% 91
Total Revenues 1,768.3 4.9% 57
Parameter Value Change Score
Return on Equity 18.0 39.4% 54
Net Cashflow -19.0 -112.2% 93
Capital Expenditure -123.7 -2.4% 68
Asset Turnover 0.4 2.6% 80
Free Cashflow 14.9 40.6% 92

* All values are TTM

The below chart reflects United Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While United Therapeutics's peer average final assessment score stands on 71.0, United Therapeutics's score is 88.

  •  UTHR
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 10 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 11 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 12 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 14 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 15 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 16 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 17 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 18 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. United Therapeutics's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. The company is trading near it's 12-month high, which signals an attack on the resistance price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), United Therapeutics's stock appears overbought. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 234.02
52W Low 166.16
52W High 241.14
5D MA 237.46
50D MA 205.16
200D MA 196.41
MACD 8.32
RSI 79.22
STOCH 71.15

Balance Sheet Analysis

Overall, United Therapeutics's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. United Therapeutics publishes impressive results related to book value factors in this report. Specifically, price to book ratio (P/B) now sits at 2.6 and represents a 5.2% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. The company's book value factors component, therefore, received a grade of 88. Also, The company's assets section could set high expectations for United Therapeutics's future attractiveness, as they went to 5359.8, which is a 3.7% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Therefore, its asset component earned a score of 74. That said, one metric, Equity, stood out as strongly negative. United Therapeutics published concerning equity metrics for this filing. In the current report, equity stood at 4176.3, which represents a 5.5% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Therefore, their equity movement component earned a score of 58. Therefore, the company's balance sheet earned a grade of 76.

Parameter Value Change Score
Assets 5,359.8 3.7% 74
Liabilities 1,183.5 -2.2% 61
Price to Book 2.6 5.2% 88
Cash & Equivalents 813.3 -9.1% 60
Equity 4,176.3 5.5% 58
* All values are TTM

The below chart describes United Therapeutics's performance as reflected on its balance sheet with respect to its peers. While United Therapeutics received a balance sheet score of 76, the average of its peers stands on 72.0.

  •  UTHR
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 10 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 11 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 12 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 13 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 14 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 15 1
Alkermes plc 5.0B 63 66 46 54 71 62 16 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 17 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 18 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

United Therapeutics seems to be balancing strong EBITDA and Revenue Efficiency along with an overall impressive positive income statement. United Therapeutics reported impressive EBITDA this period. At filing, EBITDA was reported as 962.8, representing 30.0% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. The company's EBITDA movement, therefore, received a grade of 91. Also, United Therapeutics's financials reveal an interesting trend for their revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. The company's revenue efficiency, therefore, received a grade of 57. That said, one metric, Return Factors, stood out as strongly negative. Return factors metrics and ratios were disappointing in this report. United Therapeutics reported a return on equity (ROE) ratio of 18.0, representing a change of 39.4% from the last report.change of 39.4% from the previous period. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. They does not yet appear to be headed in the right direction regarding these return on equity and return on assets metrics. Therefore, their return factors component earned a score of 54. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 82.

Parameter Value Change Score
EBITDA 962.8 30.0% 91
Total Revenues 1,768.3 4.9% 57
Return on Equity 18.0 39.4% 54
* All values are TTM

The below chart describes United Therapeutics's performance as reflected on its income statement with respect to its peers. While United Therapeutics received a income statement score of 82 , the average of its peers stands on 67.0.

  •  UTHR
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 10 1
Exelixis, Inc. 6.7B 54 91 54 81 11 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 12 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 14 1
Ascendis Pharma A/S 5.2B 38 68 46 54 15 1
Alkermes plc 5.0B 69 55 81 62 16 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 17 1
Novavax, Inc. 4.0B 41 89 54 75 18 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, United Therapeutics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. United Therapeutics presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -19.0, which is a change of -112.2% from the last filing. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Hence, its net cash flow earned a score of 93. Also, United Therapeutics's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. United Therapeutics recorded free cash flow of 14.9, which represents a 40.6% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. The company's free cash flow movement, therefore, received a grade of 92. That said, one metric, Capital Expenditure, stood out as particularly concerning. United Therapeutics's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -123.7, which represents a -2.4% change from the last period. This performance is all the more uninspiring relative to their peers and competitors. Its CapEx movement, therefore, received a grade of 68. Therefore, we scored its cash flow a 93.

Parameter Value Change Score
Net Cashflow -19.0 -112.2% 93
Capital Expenditure -123.7 -2.4% 68
Asset Turnover 0.4 2.6% 80
Free Cashflow 14.9 40.6% 92
* All values are TTM

The below chart describes United Therapeutics's performance as reflected on its cash flow with respect to its peers. While United Therapeutics received a cash flow score of 93, the average of its peers stands on 70.0.

  •  UTHR
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 10 1
Exelixis, Inc. 6.7B 79 90 89 83 87 11 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 12 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 13 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 14 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 15 1
Alkermes plc 5.0B 89 95 76 80 92 16 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 17 1
Novavax, Inc. 4.0B 62 38 63 54 60 18 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.